<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970046</url>
  </required_header>
  <id_info>
    <org_study_id>HR-SP2086-302</org_study_id>
    <nct_id>NCT01970046</nct_id>
  </id_info>
  <brief_title>A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase III Study to Access the Efficacy and Safety of SP2086 in Combination Therapy With Metformin in Patients With Type 2 Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the
      efficacy and safety of SP2086 in combination therapy with Metformin in patients with Type 2
      Diabetes Mellitus in Metformin monotherapy Who Have Inadequate Glycemic Control
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c (Hemoglobin A1C) at Week24</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Less Than (&lt;) 6.5% or &lt;7% HbA1c Levels</measure>
    <time_frame>week24, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in fasting plasma glucose (FPG) at Week 24,52</measure>
    <time_frame>Weeks 0-24-52</time_frame>
    <description>Change from baseline at Week 24,52 is defined as Week 24 ,52 FPG minus Week 0 FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-hour Post-meal Glucose (2-hr PMG) at Week 24</measure>
    <time_frame>Weeks 0-24</time_frame>
    <description>Change from baseline at Week 24 is defined as Week 24 2-hr PMG minus Week 0 2-hr PMG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c at Week 52</measure>
    <time_frame>week 52</time_frame>
    <description>A1C is measured as a percent. Thus, this change from baseline reflects the Week 52 HbA1c percent minus the Week 0 HbA1c percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in lipid at Week 4、8、12、24、38、52</measure>
    <time_frame>Week 4、8、12、24、38、52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 4,8,12、24、38、52</measure>
    <time_frame>Week 4、8、12、24、38、52</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo/Metformin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SP2086 (50mg b.i.d)/Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SP2086 (50mg q.d.)/Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/Metformin</intervention_name>
    <description>Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks
Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks
Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks</description>
    <arm_group_label>Placebo/Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP2086 50 mg b.i.d/Metformin</intervention_name>
    <description>Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks
Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks
Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks</description>
    <arm_group_label>SP2086 (50mg b.i.d)/Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP2086 50 mg q.d./Metformin</intervention_name>
    <description>Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks
Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks
Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks</description>
    <arm_group_label>SP2086 (50mg q.d.)/Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with type 2 diabetes mellitus

          -  subject on metformin monotherapy with stable dose ≥1500mg/d for ≥8 weeks

          -  7.5% ≤HbA1C ≤11.0% at screening,7.0% ≤HbA1C ≤10.5% after run-in

          -  Body Mass Index: ≥19 and ≤35 kg/m2

        Exclusion Criteria:

          1. ＜80% or ＞120% compliance with placebo treatment during the run-in period

          2. Patients used the following drugs or therapies prior to randomization:

        1) Somatropin therapy within 6 months prior to randomization 2) History of drug or alcohol
        abuse within 6 months prior to randomization 3) Participate in clinical trials of any drugs
        or medical devices within 3 months prior to randomization 4) Receive corticosteroids
        long-term (more than 7 consecutive days) oral, non-gastrointestinal administration or
        intra-articular administration within 2 months prior to randomization 5) Weight control
        drugs administration or Surgeries resulting in weight instability within 2 months prior to
        randomization 6) In investigator's opinion, patients used any drugs that interfere with
        assessment of the investigational product, or produce vital organs toxicity 4. Patients
        with history of the following diseases or proof prior to randomization:

          1. Type 1 diabetes, single gene mutation diabetes, diabetes caused by pancreatic damage
             and secondary diabetes, such as caused by Cushing's syndrome or acromegaly

          2. a history of hypertension, and after antihypertensive treatment, systolic blood
             pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg

          3. a history of acute and chronic pancreatitis or pancreatic injury that may lead to high
             risk of pancreatitis

          4. serious haematological diseases or other diseases leading to hemolyze and Red Blood
             Cell unstable (malaria、haemolytic anaemia eg. )

          5. other endocrine diseases, for example
             hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on

          6. Any organ system tumors except the local skin basal cell carcinoma that have been
             treated or not been treated within 5 years prior to randomization, regardless of
             whether there is evidence of local recurrence or metastasis ; a history or family
             history of medullary carcinoma of thyroid ; a history of multiple endocrine neoplasia

          7. Decompensated heart failure (NYHA class III and IV), unstable angina, stroke or
             transient ischemic attack, myocardial infarction, persistence and clinical
             significance arrhythmia, coronary artery bypass grafting or percutaneous coronary
             intervention within 6 months prior to randomization

          8. Acute metabolic complications (ketoacidosis, lactic acidosis or hyperosmolar coma),
             unstable proliferative retinopathy or macular degeneration within 6 months prior to
             randomization

          9. Severe trauma or acute infection that may affect blood glucose control within 4 weeks
             prior to randomization

         10. Severe chronic gastrointestinal disease or therapy that may affect drug absorption,
             such as gastrointestinal surgery

         11. With a history of mental/emotional disorder that would interfere with the subject's
             participation in the study.

        5. Patients with any laboratory parameters meet the following criteria prior to
        randomization:

          1. Aspartate Aminotransferase or alanine aminotransferase ≥ 2.0× upper normal limit(UNL)
             , and/or total bilirubin ≥ 2.0 × UNL also review confirmed within 3 days;

          2. Triglyceride＞5.64mmol/L（500mg/dl）；

          3. serum creatinine to exceed the normal range

          4. thyroid stimulating hormone to exceed the normal range, and have clinical significance

          5. blood amylase o exceed the normal range, and have clinical significance

          6. In investigator's opinion, any significant laboratory abnormalities of clinical
             significance value that interfere with assessment of this study.

        6. At Screening patients not installed pacemaker with II or III degree atrioventricular
        block, long QT syndrome or QT corrected &gt; 500 ms 7. Patients who received blood
        transfusions or blood donation≥ 400 mL or severe blood loss at least 400 mL within 8 weeks
        prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changyu Pan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changyu Pan, M.D.</last_name>
    <phone>86 10 66887329</phone>
    <email>panchy301@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huaqiong Shen, P.H.D</last_name>
    <phone>86 21 68868570</phone>
    <phone_ext>827</phone_ext>
    <email>shenhuaqiong@hrs.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changyu Pan, M.D.</last_name>
      <email>panchy301@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Changyu Pan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <last_update_submitted>October 22, 2013</last_update_submitted>
  <last_update_submitted_qc>October 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SP2086</keyword>
  <keyword>Phase III</keyword>
  <keyword>combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

